{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:16:33Z","timestamp":1791198993180,"version":"4.1.0"},"reference-count":29,"publisher":"Rockefeller University Press","issue":"11","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,24]]},"abstract":"<jats:p>The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGF\u03b2, AKT, and FOXO transcription factors (TFs). B cell lymphoma 6 (BCL6) is a transcriptional repressor whose translocation or mutation is associated with diffuse large BCL. New data now show that BCL6 is critical for the maintenance of leukemias driven by the BCR-ABL translocation (Philadelphia chromosome), suggesting that BCL6 is a novel, targetable member of the complex signaling pathways critical for leukemic stem cell survival.<\/jats:p>","DOI":"10.1084\/jem.20112087","type":"journal-article","created":{"date-parts":[[2011,10,24]],"date-time":"2011-10-24T17:34:08Z","timestamp":1319477648000},"page":"2155-2158","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks"],"prefix":"10.1084","volume":"208","author":[{"given":"Francesca","family":"Pellicano","sequence":"first","affiliation":[{"name":"F. Pellicano and T.L. Holyoake are at the Paul O\u2019Gorman Research Centre, Faculty of Medicine, University of Glasgow, Gartnavel General Hospital, Glasgow, G12 0XB, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[{"name":"F. Pellicano and T.L. Holyoake are at the Paul O\u2019Gorman Research Centre, Faculty of Medicine, University of Glasgow, Gartnavel General Hospital, Glasgow, G12 0XB, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2011,10,24]]},"reference":[{"key":"2023072522323886300_bib1","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood.V89.10.3624","article-title":"A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells","volume":"89","author":"Austin","year":"1997","journal-title":"Blood."},{"key":"2023072522323886300_bib2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nature05029","article-title":"PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR","volume":"442","author":"Bernardi","year":"2006","journal-title":"Nature."},{"key":"2023072522323886300_bib3","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood."},{"key":"2023072522323886300_bib4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell."},{"key":"2023072522323886300_bib5","doi-asserted-by":"publisher","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072522323886300_bib6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat. Genet."},{"key":"2023072522323886300_bib7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/blood-2010-11-316760","article-title":"A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia","volume":"118","author":"Chen","year":"2011","journal-title":"Blood."},{"key":"2023072522323886300_bib8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"2023072522323886300_bib9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"Duy","year":"2011","journal-title":"Nature."},{"key":"2023072522323886300_bib10","doi-asserted-by":"publisher","first-page":"10058","DOI":"10.1128\/MCB.24.22.10058-10071.2004","article-title":"FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5\/BCL6-dependent mechanism","volume":"24","author":"Fern\u00e1ndez de Mattos","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"2023072522323886300_bib11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood."},{"key":"2023072522323886300_bib12","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J. Exp. Med."},{"key":"2023072522323886300_bib13","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J. Biol. Chem."},{"key":"2023072522323886300_bib14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature."},{"key":"2023072522323886300_bib15","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1074\/jbc.M211562200","article-title":"A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells","volume":"278","author":"Komatsu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2023072522323886300_bib16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.stem.2010.09.015","article-title":"mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion","volume":"7","author":"Lee","year":"2010","journal-title":"Cell Stem Cell."},{"key":"2023072522323886300_bib17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"2023072522323886300_bib18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature."},{"key":"2023072522323886300_bib19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell."},{"key":"2023072522323886300_bib20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell."},{"key":"2023072522323886300_bib21","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2023072522323886300_bib22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","article-title":"PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice","volume":"115","author":"Peng","year":"2010","journal-title":"Blood."},{"key":"2023072522323886300_bib23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature."},{"key":"2023072522323886300_bib24","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/onc.2009.7","article-title":"Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients","volume":"28","author":"Samanta","year":"2009","journal-title":"Oncogene."},{"key":"2023072522323886300_bib25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","article-title":"Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN","volume":"95","author":"Stambolic","year":"1998","journal-title":"Cell."},{"key":"2023072522323886300_bib26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cell.2007.01.003","article-title":"FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress","volume":"128","author":"Tothova","year":"2007","journal-title":"Cell."},{"key":"2023072522323886300_bib27","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","article-title":"Jak2 is involved in c-Myc induction by Bcr-Abl","volume":"21","author":"Xie","year":"2002","journal-title":"Oncogene."},{"key":"2023072522323886300_bib28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nature04703","article-title":"Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells","volume":"441","author":"Yilmaz","year":"2006","journal-title":"Nature."},{"key":"2023072522323886300_bib29","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1084\/jem.20072316","article-title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells","volume":"205","author":"Zhou","year":"2008","journal-title":"J. Exp. Med."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/208\/11\/2155\/1740008\/jem_20112087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/208\/11\/2155\/1740008\/jem_20112087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T22:33:06Z","timestamp":1690324386000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/208\/11\/2155\/40932\/Assembling-defenses-against-therapy-resistant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,24]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,10,24]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20112087","relation":{},"ISSN":["1540-9538","0022-1007"],"issn-type":[{"value":"1540-9538","type":"electronic"},{"value":"0022-1007","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10,24]]}}}